A
Ambys Medicines
A developer of regenerative medicine therapies for serious liver diseases
About Ambys Medicines
Ambys Medicines, operating under the website ambys.com, is a pioneering biotechnology startup that is revolutionizing the medical and pharmaceutical industry. The company specializes in the development of a bio-incubator that propagates high-quality primary human hepatocytes, also known as liver cells.
The company's primary clients are pharmaceutical companies and the liver research community. Pharmaceutical companies use these liver cells to test new drugs for toxicity and safety, ensuring that they are safe for human consumption. The liver research community, on the other hand, uses these cells for the development of new therapeutics for liver failure, liver disease, and rare diseases. This innovative technology also aids in the advancement of other disease-specific research.
Ambys Medicines operates in the biotechnology market, specifically in the sector of liver cell research and drug testing. Their business model revolves around the production and supply of high-quality liver cells to their clients. The company generates revenue by selling these cells to pharmaceutical companies and research institutions.
The company's success is also attributed to its strategic partnerships. These partners provide the necessary tools, information, and support needed to achieve the company's mission of developing a consistent, high-quality source of primary human hepatocytes and applying them to multiple research and clinical applications.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Redwood City, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 65.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2021 | $47M | $300M | Takeda Ventures · Schroders · Alexandria Venture Investments · SmileGate Investment | ↗ |
| SERIES AOther financing | Aug 2018 | $60M | $240M | Takeda · Takeda Ventures · Third Rock Ventures | — |
Growth signals
Latest recorded traffic for Ambys Medicines is 120 monthly website visits, up 9.1% over the last three months. Ambys Medicines's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Takeda
Third Rock Ventures
Takeda Ventures
Schroders
Alexandria Venture Investments
SmileGate Investment
Laurion Capital Management
Other known investors3 additional known investors
Oregon Health & Science University
University of California, San Francisco
University of Illinois Urbana Champaign
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ambys Medicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ambys Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.